author-photo

Keith Mikule

AstraZeneca

26

Papers

362

Citations

Citation Trend

Filter By

Papers (18) Sort By

Journal Conference Others

Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme.

2021 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (1)
Abstract 3277: IACS-9779, a development candidate that inhibits 2,3-dioxygenase (IDO) activity by blocking heme incorporation into IDO apoenzyme

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models

2019 Scientific Reports
Show All
- Source
- Cite
- Save
Citations (83)
Abstract 5690: Characterization of tumor growth and immune microenvironment in humanized NOG-EXL mice implanted with A549, MDA-MB-436 and A375 cells

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (16)
Abstract 1724: Evaluation of niraparib in combination with anti-PD1/anti-PD-L1 in preclinical models

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (3)
Abstract LB-071: Discovery of an imidazopyridine series of potent human IDO1 inhibitors with robust target engagement in a preclinical tumor model

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models

2018 Oncotarget
Show All
- Source
- Cite
- Save
Citations (51)
Modulating the strength of hydrogen bond acceptors to achieve low Caco2 efflux for oral bioavailability of PARP inhibitors blocking centrosome clustering

2016 Bioorganic & Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (4)
Abstract 4353: Preclinical evaluation of the PARP inhibitor niraparib and cytotoxic chemotherapy alone or in combination in a panel of 25 triple-negative breast cancer PDX models: Relevance of BRCA mutations, HRD status and other biomarkers

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)